Mira P. Patel

Mira P. Patel

Auto-generated profile, based on publicly available information

Mira P. Patel

Global Blood Therapeutics Inc., South San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2016 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
DODonna Oksenberg
Donna Oksenberg
KDKobina Dufu
Kobina Dufu
MPMira P. Patel
Mira P. Patel
CCChihyuan Chuang
Chihyuan Chuang
ZLZhe Li
Zhe Li
DADavid Archer
David Archer
Summary: A major driver of the pathophysiology of sickle cell disease (SCD) is polymerization of deoxygenated haemoglobin S (HbS), which leads to sickling and destruction of red blood cells (RBCs) and end‐organ damage. Pharmacologically increasing the proportion of oxygenated HbS in RBCs may inhibit polymerization, prevent sickling and provide long term disease modification. We report that GBT440, a small molecule which binds to the N‐terminal α chain of Hb, increases HbS affinity for oxygen, delays in vitro HbS polymerization and prevents sickling of RBCs. Moreover, in a murine model of SCD, GBT440 extends the half‐life of RBCs, reduces reticulocyte counts and prevents ex vivo RBC sickling. Importantly, oral dosing of GBT440 in animals demonstrates suitability for once daily dosing in humans and a highly selective partitioning into RBCs, which is a key therapeutic safety attribute. Thus, GBT440 has the potential for clinical use as a disease‐modifying agent in sickle cell patients.